The FDA submission and strong clinical traction suggest a potential inflection point. With cash now sufficient for 2+ years of operations and commercial launch expected in 2026, traders should monitor FDA feedback, kit sales conversion from engaged centers, and upcoming peer-reviewed publications on CM-score performance.
Price Chart
Executive Summary
Insight Molecular Diagnostics (IMDX) reported strong revenue growth for 2025, submitted its GraftAssureDx kidney transplant test for FDA review, and secured $26 million in financing to support commercialization and expansion into heart transplantation. Despite significant net losses, the company is transitioning toward commercialization with growing clinical engagement and favorable head-to-head data supporting its technology.
Key Financial Metrics
Key Facts
- Submitted GraftAssureDx for FDA review on March 25, 2026 — first kitted dd-cfDNA assay under regulatory review for transplant rejection.
- Completed $26 million registered direct offering in February 2026, netting $24.6 million to fund commercialization and R&D expansion.
- Revenue grew 115% YoY to $4.1 million in 2025, with Q4 revenue at $1.1 million; gross margin improved to 56.7% from 39.3%.
- Engaged with 37 U.S. transplant centers (over 25% of annual U.S. transplants) and 11 internationally via RUO and registry programs.
- Second favorable head-to-head study vs. leading centralized test reinforces clinical differentiation and supports in-house adoption.
- Non-GAAP net loss in Q4 2025 was $8.7 million ($0.27/share), significantly better than GAAP loss of $23.0 million ($0.72/share).
- Cash balance post-financing is ~$37.5 million (Q4 cash of $12.9M + $24.6M net proceeds), funding operations into 2027.
Financial Impact
Revenue up 115% YoY to $4.1M; gross margin expanded 17.4 pts to 56.7%; $24.6M net cash raised; R&D up 62% to $15.9M
Risk Factors
- FDA review could be delayed if questions stop the 150-day clock.
- Commercial adoption may lag despite clinical interest due to hospital procurement cycles.
- High cash burn (~$7.5M/quarter expected in 2026) remains a concern if revenue ramp is slower than anticipated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263407 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $4.43 | awaiting T+60 | — | $3.00 (−32.28%) |
Mar 26, 2026 30w ago | Press Release | $3.56 $5.46 | ▲ +53.43% | ▲ +37.36% | $3.00 (−15.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers